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INTRODUCTION
The 4th edition of the World Health Organization (WHO) 
classification of breast tumors defines encapsulated papillary 
carcinoma (EPC) as a variant of papillary carcinoma that is 
surrounded by a thick fibrous capsule and lacks myoepithelial 
cells (MECs) within the papillae and around the periphery of 
the tumor, as demonstrated by a panel of immunohistochem-
istry (IHC) markers [1]. According to the classical breast pa-
thology textbooks, the lack of MECs suggests malignant clin-
ical behavior breast neoplasms; however, EPC is reported to 
be a relatively indolent tumor, and very few cases have shown 
axillary lymph node metastases [2]. Several hypotheses about 
the biological nature of EPC exist; for example, a tumor in 
transition from an in situ to an invasive phase and an indolent 
low-grade carcinoma with pushing rounded invasion [3]. The 
WHO Working Group advocates that EPC should be staged 
as an in situ lesion (Tis) [1,4]. EPC is a well-circumscribed tu-
mor of the elderly and can be accompanied by a conventional 
in situ and/or invasive carcinoma component, most frequently 
in the form of invasive no special type (NST) carcinoma [5]. 
The present case perfectly matches these characteristics. 
Apocrine breast neoplasms are characterized by a specific 
histologic appearance, which resembles apocrine metaplasia 
on hematoxylin and eosin (H&E) stained slides. Such tumors 
consist of abundant granular eosinophilic cytoplasm and large 
nuclei, with prominent nucleoli [1]. This subset of breast tu-
mors is generally estrogen receptor (ER) negative, progester-
one receptor (PR) negative, and androgen receptor (AR) posi-
tive [6]. Our previous results suggest that these tumors are 
also almost uniformly positive for growth hormone-releasing 
hormone-receptor (GHRH-R) [7,8]. The majority of apocrine 
carcinomas can be considered special variants of NST carci-
nomas, although apocrine differentiation has also been re-
ported in several special-type cancers, including EPC [9-12].
CASE REPORT
On a breast screening mammography, a 70-year-old woman 
was diagnosed with a complex breast lesion in the upper-outer 
quadrant of her right breast. The lesion contained a cystic part 
and a neighboring spiculated area, which was suggestive of an 
infiltrative component (Figure 1A-1C). Fine needle aspiration 
cytology of the lump showed atypical apocrine epithelial cells, 
but confirmation of the suspected malignancy was not possible. 
The subsequent core needle biopsy disclosed an invasive car-
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Apocrine encapsulated papillary carcinoma (EPC) of the breast 
is a rare neoplasm, and only 10 cases have been reported in the 
literature to date. Although EPC by definition lacks a peripheral 
myoepithelial layer, all previously published apocrine EPC cases 
were clinically indolent and lacked a conventional invasive com-
ponent. Herein, we report the 11th case of apocrine EPC, which 
had a conventional invasive carcinoma component and provides 
evidence of the malignant potential of this entity. We postulate 
that apocrine EPC is most likely a morphological variant of con-
ventional EPC, with the same unpredictable malignant potential 
as non-apocrine cases.
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Figure 1. Imaging and gross findings. Architecture of the dual tumor with mammography (A), pneumocystography (B), ultrasound (C), and gross mor-
phology (D). Note the sharply outlined component, showing a clear cystic nature (B, C) with an intraluminal mass. In connection with the intracystic 
tumor an ill-defined lesion with coarse microcalcifications (A) suggestive of an infiltrative tumor component is also present.
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Figure 2. Histological characteristics and immunoprofile. (A) An intracystic papillary component (right) is surrounded by a thick fibrous capsule and an 
invasive carcinoma (left) component on the low-power view of the lesion (H&E stain, ×1.2). (B) The intracystic part shows a prominent papillary archi-
tecture and apocrine cytomorphology (H&E stain, ×5). (C) The invasive carcinoma part also demonstrates apocrine cytomorphology (H&E stain, 
×20). The p63 (D, H&E stain, ×5), cytokeratin 5 (E, H&E stain, ×5), and CD10 (F, H&E stain, ×5) immunohistochemistry markers demonstrate the 
absence of myoepithelial cells in the intracystic papillary component; note the positive internal control and the focal luminal CD10 expression (insert) 
frequently observed in apocrine lesions [13]. As an evidence for apocrine differentiation, both the encapsulated papillary carcinoma component (G-I, 
×15) and the invasive component (J-L, ×20) express androgen receptor (G and J, respectively), gross cystic disease fluid protein 15 (H and K, re-
spectively), and growth hormone-releasing hormone-receptor (I and L, respectively).
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cinoma with apocrine differentiation. The patient underwent 
breast-conserving surgery with a sentinel lymph node biopsy.
The gross examination discovered a correlating dual lesion, 
which consisted of an intracystic proliferation and a tumor 
mass that was ill-defined and infiltrative in appearance (Figure 
1D). Microscopically, the intracystic portion showed a thick 
fibrous capsule, an intraluminal dominantly papillary, partial-
ly solid proliferation, and a total absence of MEC, under H&E 
staining and p63, cytokeratin 5, smooth muscle actin, and 
CD10 IHC (Figure 2) [13]. The ill-defined component repre-
sented a NST invasive carcinoma with desmoplasia. Both the 
intracystic and infiltrative parts showed cytomorphologies 
that agreed with apocrine differentiation, with eosinophilic 
granular cytoplasm, large nuclei, and prominent nucleoli. 
Small apocrine ductal carcinoma in situ foci were also present. 
The invasive tumor was categorized as grade 2 (2+3+ 2 = 7 
points for tubule formation, pleomorphism, and mitotic activity, 
respectively), according to the Elston-Ellis modification of the 
Scarff-Bloom-Richardson system. With respect to prognostic 
and predictive IHC markers, all tumor components were neg-
ative for ER, PR, and human epithelial growth factor receptor 
2 (HER2), and showed a Ki-67 labeling index of 15%. The tu-
mor was positive for AR, with an Allred score of 8, gross cys-
tic disease fluid protein 15 (GCDFP-15) and GHRH-R were 
both observed in the intracystic papillary carcinoma, and the 
tumor contained an infiltrative NST carcinoma component 
(Figure 2). Based on our findings, the diagnosis of apocrine 
EPC of the breast, associated with an invasive NST (ductal) 
carcinoma with apocrine differentiation, was established.
DISCUSSION
EPC of the breast, formerly known as intracystic and en-
cysted papillary carcinomas, is a rare tumor type that repre-
sents approximately 1% of all breast carcinomas. The previ-
ously published 10 cases of apocrine EPC (A-EPC) all lacked 
a conventional invasive component and have been described 
to have indolent clinical behaviors (Table 1) [9-12]. MECs are 
sometimes very hard or even impossible to identify around 
benign cystic apocrine glands [14,15], and they may virtually, 
partially, or completely lack benign cystic apocrine lesions 
with papillary proliferations [15]. Therefore, the definition 
that was used for classic EPCs should be applied to apocrine 
variants with caution. This doubt was also formulated in the 
first series of such lesions, where the term encapsulated apo-
crine papillary carcinoma was used, based on compliance 
with the WHO terminology: a papillary lesion without MECs 
in the papillary area and at the periphery. The authors also 
stressed that the malignant potential of A-EPC has not yet 
been proven [9]. A characteristic feature of EPCs, the presence 
of a thick fibrous capsule, was lacking in at least some of the 
five cases, as shown in Figure 8 of the paper [9]. The present 
A-EPC case, on the other hand, displayed a thick fibrous cap-
sule and a threefold variation in nuclear caliber. This case is 
unique in the sense that it represents a two-component tumor, 
with an EPC and a conventional invasive NST component, 
both of which demonstrate apocrine differentiation. The re-
ported case, therefore, may provide proof that A-EPC has the 
potential to display the same disease spectrum as convention-
al EPC, including an association with ductal carcinoma in situ 
and invasive carcinoma [5]. We therefore propose that A-EPCs 
Table 1. Patient information, treatment, and outcome of previously published apocrine EPCs and present case
Case Age (yr) Clinical presentation Surgical procedure Radiation
Systemic 
therapy
Follow-up 
(mo)
Recurrence Status
1 [9] 44 Palpable mass Left partial mastectomy No No 36 None Alive
2 [9] 44 Recurrent cyst Left partial mastectomy+sentinel node 
biopsy
42.5 Gy in 16 
fractions
No 17 None Alive
3 [9] 84 Bilateral recurrent cysts Left partial mastectomy No No 41 None Alive
4 [9] 50 Bilateral recurrent cysts Left partial mastectomy+re-excision 
+sentinel node biopsy
No No 7 None Alive
5 [9] 50 Recurrent cyst Left partial mastectomy+sentinel node 
biopsy
No No 3 None Alive
6 [11] 49 Screening-detected Breast-conserving surgery No No 22 None Alive
7 [10] 50 Palpable mass Right partial mastectomy NA NA NA None Alive
8 [12] 68 Palpable mass Left partial mastectomy+sentinel node 
biopsy
No No 11 None Alive
Present 70 Palpable mass Right partial mastectomy+sentinel 
node biopsy
50 Gy Denied 8 None Alive
Two previously published apocrine EPC cases are not shown, as no clinical information was available in the report.
EPC=encapsulated papillary carcinoma; NA=not applicable.
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are not necessarily as indolent as previously suggested by 
the nine pure A-EPC lesions. Our case implies that the clinical 
behavior of A-EPCs falls into the same unpredictable malignant 
potential category as the behavior of classical EPCs, rather 
than into a completely indolent category, as put forward by 
the first reported cases.
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